Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer - Summary - MDSpire

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • By

  • Meghna S. Trivedi

  • Joseph M. Unger

  • N. Lynn Henry

  • Amy K. Darke

  • Daniel L. Hertz

  • Thomas H. Brannagan

  • Stephanie J. Reyes

  • Bryan P. Schneider

  • William J. Irvin

  • Amanda R. Hathaway

  • Amy C. Vander Woude

  • Vinay K. Gudena

  • Paula Cabrera-Galeana

  • Mary Orsted

  • Michael LeBlanc

  • Michael J. Fisch

  • Dawn L. Hershman

  • April 10, 2026

  • 0 min

Share

Objective:

To develop and validate a predictive model for assessing the risk of taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane-based chemotherapy, aiming to enhance clinical decision-making.

Key Findings:
  • TIPN occurs in up to 70% of patients treated with taxanes.
  • Identified risk factors include demographic, lifestyle, comorbid conditions, and treatment-related factors.
  • The model aims to differentiate between high-risk and low-risk patients for TIPN, with a focus on predictive accuracy.
Interpretation:

The study provides a structured approach to predict TIPN risk, potentially guiding clinical decisions regarding taxane treatment and dose modifications, thereby improving patient management.

Limitations:
  • Results may vary due to the observational nature of the study.
  • Potential biases from self-reported data and limited generalizability to diverse populations, particularly in different ethnic groups.
Conclusion:

The predictive model for TIPN risk could improve management strategies for patients undergoing taxane-based chemotherapy, although further validation is necessary.

Original Source(s)

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • by Meghna S. Trivedi, Joseph M. Unger, N. Lynn Henry, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan, Stephanie J. Reyes, Bryan P. Schneider, William J. Irvin, Amanda R. Hathaway, Amy C. Vander Woude, Vinay K. Gudena, Paula Cabrera-Galeana, Mary Orsted, Michael LeBlanc, Michael J. Fisch, Dawn L. Hershman

  • April 10, 2026

Related Content

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC